Loading...
•
Dec 31, 2025
Lineage Q4 2025 Earnings Report
Lineage reported higher fourth quarter revenue and achieved net income driven by collaboration milestone revenue.
Key Takeaways
Lineage generated approximately $6600000 in revenue during the fourth quarter of 2025, primarily from collaboration activities following a milestone under its Roche agreement and a new research collaboration. The company reported net income of about $900000 despite increased operating expenses driven by higher research and development spending.
Fourth quarter revenue increased to approximately $6600000 from $2900000 year over year.
Net income was approximately $900000 compared with a net loss of $3300000 in the prior year period.
Research and development expenses increased significantly to $8200000 due to program expansion.
Operating loss was approximately $6500000 as operating expenses rose to $13200000.
Revenue by Segment
Forward Guidance
Lineage expects its existing cash and equivalents to support planned operations into the second quarter of 2028 while continuing development of its cell therapy pipeline and advancing collaboration programs.
Positive Outlook
- Cash and equivalents expected to fund operations into Q2 2028.
- Milestone achievement under Roche and Genentech collaboration supports revenue growth.
- Advancement of OpRegen cell therapy program and ongoing Phase 2a GAlette study.
- New research collaboration with William Demant Invest to support ReSonance program.
- Manufacturing progress with AlloSCOPE platform supporting scalable cell therapy production.
Challenges Ahead
- Operating expenses increased significantly year over year.
- R&D spending is rising as programs advance.
- Clinical development risk remains for early-stage pipeline programs.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...